Financial Reports Latest Updates Industry Maps Economic Calendar

CytomX Therapeutics, Inc. (CTMX) Annual Reports

Q: Where can I read CytomX Therapeutics, Inc. (CTMX) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

CytomX Therapeutics, Inc. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1501989 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$1.4M	$18.7M	-92.4%
Operating income	$-23.8M	$-1.3M	-1749.2%
Net income	$-20.7M	$-154,000	-13319.5%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 1.42 mn Net income -20.7 mn

Show table：Income statement

Item	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	0.89	0.64	0.67	1.92	1.86	1.74	2.04	1.94	1.99	2.22	3.09	3.45	6.27	11.7	8.75	24.1	27.1	14.2	21.3	12.5	11.5	29.5	9.01	10.7	8.28	49.6	16.6	17.8	7.08	16.0	16.3	17.6	11.1	17.1	18.2	16.9	0.95	23.5	24.7	26.4	26.6	41.5	25.1	33.4	38.1	50.9	18.7	5.96	0.66	10.3	1.42
Operating income	-15.0	—	—	-3.46	-4.66	-4.87	-5.54	-11.3	-11.5	-16.2	-14.3	-14.9	-14.2	-8.61	-25.4	-11.0	-1.25	-15.6	-13.3	-23.2	-25.8	-16.6	-31.2	-25.7	-37.4	-2.79	-16.1	-14.9	-24.1	-15.6	-19.2	-22.6	-34.9	-24.0	-24.7	-23.9	-28.7	-5.65	-3.35	3.12	-0.61	11.7	-8.45	4.11	17.7	22.6	-1.29	-15.8	-27.9	-19.7	-23.8
Net income	-15.1	-17.0	-4.93	-3.59	-4.79	-6.21	-5.81	-11.9	-11.5	-16.0	-14.2	-14.7	-14.0	-8.26	-25.2	-10.3	0.62	-15.5	-13.4	-23.4	-32.2	-14.1	-29.0	-23.7	-35.5	12.2	-15.7	-14.7	-24.0	-15.6	-19.2	-22.6	-34.8	-23.9	-24.2	-23.3	-27.9	-3.31	-1.09	2.99	0.84	13.8	-6.53	5.74	18.9	23.5	-0.15	-14.2	-26.5	-18.3	-20.7

Balance sheet

Quarterly · In mn (USD)

Total assets 381 mn Total liabilities 79.2 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	—	66.8	—	—	115	190	185	200	183	188	167	341	376	389	367	367	473	445	405	367	335	303	400	367	340	324	400	271	241	310	268	233	200	237	212	188	201	183	167	143	124	107	86.6	165	149	144	353	373
Total assets	—	—	—	—	73.1	—	—	125	197	192	207	193	199	178	352	387	398	376	377	483	457	445	405	373	341	437	402	375	359	434	402	371	339	297	260	226	261	235	209	221	202	185	159	139	121	98.5	175	158	152	359	381
Current liabilities	—	—	—	—	11.2	—	—	14.0	15.7	17.0	22.2	23.7	35.8	37.1	60.6	71.2	61.1	69.7	83.2	86.3	97.9	96.2	78.7	76.1	85.6	106	98.8	102	101	98.0	93.4	99.8	106	103	99.4	97.8	153	151	141	147	156	145	143	119	85.8	50.2	39.2	41.0	46.6	34.0	39.9
Total liabilities	—	—	—	—	74.9	—	—	71.8	71.2	79.2	106	103	121	104	300	342	328	327	336	325	326	322	304	290	290	367	344	327	309	288	271	260	250	229	211	198	347	321	294	272	249	216	190	162	121	73.5	55.1	50.9	52.6	39.4	79.2
Equity	-44.3	—	—	—	-78.5	—	—	-106	126	113	101	89.4	78.5	73.8	52.2	45.5	69.9	49.6	41.1	158	131	123	102	82.1	51.1	69.8	58.8	48.1	49.8	146	131	112	89.4	68.2	48.7	28.5	-85.8	-86.6	-85.0	-51.2	-47.5	-31.7	-31.2	-23.4	-0.46	25.1	120	107	99.0	320	302

Cash flow

Quarterly · In mn (USD)

Operating -18.1 mn Investing 5.95 mn Financing 0.51 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-8.01	—	—	36.2	-4.40	-5.37	-6.11	-7.77	-8.17	-5.54	15.8	-14.2	1.94	-19.1	173	-5.74	22.0	-14.6	-26.6	-5.55	-28.7	-39.0	-48.6	-23.3	-29.5	-49.7	97.1	-24.7	-17.4	-29.9	-28.2	-29.7	-31.2	-41.3	-34.2	-33.8	-1.39	9.35	-25.2	-18.2	-22.0	-26.0	-19.6	-20.7	-19.9	-21.0	-15.8	-15.6	-23.2	-25.6	-18.1
Investing	-0.73	—	—	-1.00	-0.66	-52.0	-29.0	1.30	-50.9	13.6	-21.5	11.3	42.5	-0.79	13.3	15.9	-150	-23.4	16.6	-3.18	15.8	-18.6	6.94	38.5	52.9	2.44	49.5	-90.1	19.4	59.0	-46.0	9.73	-0.24	-0.74	-0.41	-0.41	99.8	-147	26.0	-42.9	12.9	44.9	21.5	18.2	15.1	30.6	-76.4	0.44	-14.4	-193	5.95
Financing	2.70	—	—	9.41	16.1	0.84	73.1	-3.18	82.7	0.04	0.21	0.25	0.5	0.89	0.67	1.16	21.1	2.60	0.72	136	0.72	0.47	0.7	0.06	0.4	2.16	1.55	0.17	13.0	109	0.69	0.1	0.68	0.01	0.45	0	0.19	0	0.32	29.7	0.24	0.17	5.10	0	2.25	0	93.5	0.25	16.6	234	0.51
Cash at period end	8.70	—	—	53.3	64.4	7.82	45.8	36.2	59.8	67.9	62.4	59.8	105	85.7	273	284	178	142	133	260	248	190	149	165	188	143	291	177	192	330	256	236	206	163	129	95.0	194	56.4	57.5	26.0	17.2	36.2	43.3	40.6	38.0	47.6	49.0	34.2	12.7	28.8	17.2

Profitability

Quarterly · %

Operating margin -1677.1% Net margin -1457.4%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	-1684.2%	—	—	-180.9%	-250.3%	-279.4%	-271.3%	-581.2%	-579.7%	-727.9%	-460.8%	-431.9%	-226.9%	-73.9%	-289.9%	-45.7%	-4.6%	-110.2%	-62.1%	-185.3%	-225.0%	-56.2%	-346.5%	-240.1%	-451.5%	-5.6%	-97.2%	-83.7%	-340.1%	-97.8%	-117.9%	-128.7%	-313.5%	-139.9%	-136.2%	-141.5%	-3032.2%	-24.1%	-13.5%	11.8%	-2.3%	28.1%	-33.6%	12.3%	46.4%	44.4%	-6.9%	-264.4%	-4213.0%	-191.8%	-1677.1%
Net margin	-1705.3%	-2677.8%	-740.2%	-187.4%	-257.2%	-356.5%	-284.2%	-612.2%	-577.8%	-721.0%	-458.2%	-424.5%	-223.7%	-70.9%	-288.1%	-42.4%	2.3%	-109.2%	-63.0%	-187.3%	-281.0%	-47.9%	-321.3%	-221.2%	-428.3%	24.6%	-94.4%	-82.7%	-339.0%	-97.4%	-118.1%	-128.4%	-312.8%	-139.4%	-133.1%	-137.7%	-2954.8%	-14.1%	-4.4%	11.3%	3.1%	33.3%	-26.0%	17.2%	49.5%	46.2%	-0.8%	-238.6%	-3998.5%	-177.9%	-1457.4%

Returns & leverage

Quarterly · %

ROE -37.8% ROA -28.6% Debt ratio 20.8%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	—	—	-148.9%	-40.1%	-52.9%	—	-57.6%	-54.8%	-81.0%	-85.6%	-58.1%	-81.6%	-82.6%	-51.0%	-84.3%	-96.7%	-138.5%	-82.6%	-112.3%	-78.9%	-78.1%	-82.4%	-83.6%	-64.8%	-77.5%	-101.9%	-132.5%	-93.9%	-117.4%	-151.5%	-5475.0%	—	—	—	—	—	—	—	—	—	108.2%	66.8%	-35.3%	-34.3%	-37.8%
ROA	—	—	—	—	-41.5%	—	—	-23.0%	-26.2%	-23.5%	-25.9%	-35.5%	-29.7%	-27.6%	-22.3%	-19.9%	-14.4%	-18.2%	-10.6%	-11.9%	-19.8%	-20.3%	-25.3%	-23.1%	-25.6%	-17.2%	-15.5%	-14.3%	-12.1%	-16.1%	-18.3%	-21.8%	-26.4%	-27.5%	-31.8%	-35.5%	-33.1%	-29.6%	-23.7%	-13.1%	-0.3%	7.9%	6.0%	7.7%	19.8%	29.4%	28.7%	18.9%	-12.8%	-25.8%	-28.6%
Debt ratio	—	—	—	—	102.5%	—	—	57.5%	36.1%	41.3%	51.1%	53.6%	60.6%	58.5%	85.2%	88.3%	82.4%	86.8%	89.1%	67.3%	71.4%	72.4%	75.0%	78.0%	85.0%	84.0%	85.4%	87.2%	86.1%	66.4%	67.5%	69.9%	73.7%	77.0%	81.3%	87.4%	132.9%	136.9%	140.7%	123.2%	123.5%	117.2%	119.6%	116.9%	100.4%	74.6%	31.5%	32.1%	34.7%	11.0%	20.8%

Revenue & profit

Year-to-date · In mn (USD)

Revenue 11.7 mn Net income -38.9 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 381 mn Total liabilities 79.2 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -43.6 mn Investing -187 mn Financing 235 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -372.2% Net margin -333.3%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -37.8% ROA -28.6% Debt ratio 20.8%

Revenue & profit

Annual · In mn (USD)

Revenue 76.2 mn Net income -17.4 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	5.08	7.71	15.0	71.6	59.5	57.5	91.1	61.0	53.2	101	138	76.2
Operating income	—	-33.2	-59.6	-46.3	-77.9	-111	-57.9	-92.4	-101	-6.48	25.0	-22.4
Net income	-30.3	-35.4	-58.9	-43.1	-84.6	-102	-42.2	-92.2	-99.3	-0.57	31.9	-17.4

Balance sheet

Annual · In mn (USD)

Total assets 152 mn Total liabilities 52.6 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	66.8	190	188	389	445	303	324	310	237	183	107	144
Total assets	73.1	197	199	398	457	341	359	339	261	202	121	152
Current liabilities	11.2	15.7	35.8	61.1	97.9	85.6	101	106	153	156	85.8	46.6
Total liabilities	74.9	71.2	121	328	326	290	309	250	347	249	121	52.6
Equity	-78.5	126	78.5	69.9	131	51.1	49.8	89.4	-85.8	-47.5	-0.46	99.0

Cash flow

Annual · In mn (USD)

Operating -75.6 mn Investing -59.7 mn Financing 110 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	—	-27.4	-2.03	170	-75.5	-140	5.26	-119	-111	-56.0	-86.2	-75.6
Investing	—	-131	45.9	-121	5.93	79.7	-18.7	22.5	98.3	-151	99.7	-59.7
Financing	—	153	1.00	23.8	140	1.63	16.9	110	0.65	30.2	7.52	110
Cash at period end	64.4	59.8	105	178	248	188	192	206	194	17.2	38.0	12.7

Profitability

Annual · %

Operating margin -29.4% Net margin -22.8%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	—	-430.5%	-396.1%	-64.6%	-130.9%	-192.9%	-63.6%	-151.5%	-190.6%	-6.4%	18.1%	-29.4%
Net margin	-597.0%	-458.7%	-391.5%	-60.2%	-142.2%	-177.8%	-46.3%	-151.2%	-186.8%	-0.6%	23.1%	-22.8%

Returns & leverage

Annual · %

ROE -35.3% ROA -12.8% Debt ratio 34.7%

Show table：Returns & leverage

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	-148.9%	-57.6%	-58.1%	-84.3%	-112.3%	-83.6%	-132.5%	-5475.0%	—	—	-35.3%
ROA	-41.5%	-26.2%	-29.7%	-14.4%	-19.8%	-25.6%	-12.1%	-26.4%	-33.1%	-0.3%	19.8%	-12.8%
Debt ratio	102.5%	36.1%	60.6%	82.4%	71.4%	85.0%	86.1%	73.7%	132.9%	123.5%	100.4%	34.7%

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read CytomX Therapeutics, Inc. (CTMX) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.